Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac (CVAC) EBITDA (2019 - 2025)

Historic EBITDA for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $319.4 million.

  • CureVac's EBITDA fell 1399.24% to $319.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $395.2 million, marking a year-over-year decrease of 842.39%. This contributed to the annual value of $189.9 million for FY2024, which is 16435.62% up from last year.
  • CureVac's EBITDA amounted to $319.4 million in Q3 2025, which was down 1399.24% from $67.7 million recorded in Q2 2025.
  • CureVac's 5-year EBITDA high stood at $371.4 million for Q3 2024, and its period low was -$124.0 million during Q4 2022.
  • In the last 5 years, CureVac's EBITDA had a median value of $61.6 million in 2022 and averaged $73.4 million.
  • Per our database at Business Quant, CureVac's EBITDA plummeted by 187017.13% in 2022 and then soared by 80037.21% in 2024.
  • CureVac's EBITDA (Quarter) stood at -$6.3 million in 2021, then tumbled by 1870.17% to -$124.0 million in 2022, then grew by 23.62% to -$94.7 million in 2023, then skyrocketed by 50.57% to -$46.8 million in 2024, then skyrocketed by 782.45% to $319.4 million in 2025.
  • Its EBITDA was $319.4 million in Q3 2025, compared to $67.7 million in Q2 2025 and $54.9 million in Q1 2025.